Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2022

01-01-2022 | Editorial

Tips for Busy Clinicians to Gauge Conclusions from Clinical Trials

Authors: Jeffrey L Jackson, MD MPH, Allan Detsky, MD PhD, Akira Kuriyama, MD, DrPH, PhD

Published in: Journal of General Internal Medicine | Issue 1/2022

Login to get access

Excerpt

One of the problems clinicians face is knowing how much to trust conclusions drawn from the results of clinical trials. Trialists design studies to maximize the chance that they will detect differences in outcomes and label those differences as statistically significant. To achieve statistical significance, the difference either needs to be sufficiently large, the sample size needs to be large, or the groups compared need to have sufficiently small variation. Trialists can increase the chance of finding sufficiently large differences by selecting populations at high risk of the outcome and can decrease variation by choosing relatively homogenous populations. Clinical research is very expensive, both for patients and trialists. Because of ethical, economic, and pragmatic reasons, studies are powered to be barely statistically significant, based on estimates of the size of differences that are deemed clinically important (and to some extent expected) and variation. Design issues in the planning stages of trials such as desired power (and thus the sample size required to achieve that power) are fundamentally economic. The incremental benefit derived from not missing a true difference in outcomes (measured by estimating the value of health benefits for patients who will use an effective therapy) is balanced against the incremental cost of increasing the trial power and sample size (to look for small differences).1 Missing a true difference means either people will not be offered effective therapies or the trial needs to be repeated. …
Literature
1.
go back to reference Detsky AS. Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chron Dis. 1985. 38(9):753-765CrossRef Detsky AS. Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chron Dis. 1985. 38(9):753-765CrossRef
3.
go back to reference Ho, AK. The Fragility Index for Assessing the Robustness of the Statistically Significant Results of Experimental Clinical Studies. J Gen Intern Med. Ho, AK. The Fragility Index for Assessing the Robustness of the Statistically Significant Results of Experimental Clinical Studies. J Gen Intern Med.
5.
go back to reference Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and tetracyclic antidepressants for the prophylaxis of frequent episodic or chronic tension-type headache in adults. J Gen Intern Med. 2017;32(12):1351-1358.CrossRef Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and tetracyclic antidepressants for the prophylaxis of frequent episodic or chronic tension-type headache in adults. J Gen Intern Med. 2017;32(12):1351-1358.CrossRef
6.
go back to reference Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 5/26/2004 2004;291(20):2457-2465. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 5/26/2004 2004;291(20):2457-2465.
Metadata
Title
Tips for Busy Clinicians to Gauge Conclusions from Clinical Trials
Authors
Jeffrey L Jackson, MD MPH
Allan Detsky, MD PhD
Akira Kuriyama, MD, DrPH, PhD
Publication date
01-01-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 1/2022
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07037-4

Other articles of this Issue 1/2022

Journal of General Internal Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.